VASCULAR AND RENAL MECHANISMS OF PREECLAMPSIA

Overview

Journal Curr Opin Physiol

Date 2023 Apr 3

PMID 37009057

Authors

Xi Wang

Corbin A Shields

Ubong Ekperikpe

Lorena M Amaral

Jan Michael Williams

Denise C Cornelius

Affiliations

Soon will be listed here.

Abstract

Preeclampsia (PE) is a multisystem obstetric disorder that affects 2-10% of pregnancies worldwide and it is a leading cause of maternal and fetal morbidity and mortality. The etiology of PE development is not clearly delineated, but since delivery of the fetus and placenta often leads to symptom resolution in the most cases of PE, it is hypothesized that the placenta is the inciting factor of the disease. Current management strategies for PE focus on treating the maternal symptoms to stabilize the mother in an attempt to prolong the pregnancy. However, the efficacy of this management strategy is limited. Therefore, identification of novel therapeutic targets and strategies is needed. Here, we provide a comprehensive overview of the current state of knowledge regarding mechanisms of vascular and renal pathophysiology during PE and discuss potential therapeutic targets directed at improving maternal vascular and renal function.

Citing Articles

Renal Function and the Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Normal Pregnancy and Pre-Eclampsia.

Tsikouras P, Nikolettos K, Kotanidou S, Kritsotaki N, Oikonomou E, Bothou A J Clin Med. 2025; 14(3).

PMID: 39941563 PMC: 11818630. DOI: 10.3390/jcm14030892.

Antihypertensive therapy responsiveness and adverse outcomes in preeclampsia: insights into molecular mechanisms underlying cardiovascular and renal complications.

Luizon M, Pereira D, Mamede I, Ceron C, Cavalli R, Palei A Front Pharmacol. 2023; 14:1281382.

PMID: 38074158 PMC: 10702581. DOI: 10.3389/fphar.2023.1281382.

References

Tenorio M, Ferreira R, Moura F, Bueno N, Goulart M, Oliveira A . Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2018; 28(9):865-876. DOI: 10.1016/j.numecd.2018.06.002. View

Burwick R, Easter S, Dawood H, Yamamoto H, Fichorova R, Feinberg B . Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension. 2014; 64(4):833-8. DOI: 10.1161/HYPERTENSIONAHA.114.03456. View

Turgut A, Ozler A, Goruk N, Tunc S, Sak M, Evsen M . Serum levels of the adipokines, free fatty acids, and oxidative stress markers in obese and non-obese preeclamptic patients. Clin Exp Obstet Gynecol. 2015; 42(4):473-9. View

Makris A, Yeung K, Lim S, Sunderland N, Heffernan S, Thompson J . Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension. 2016; 67(6):1263-72. PMC: 4867111. DOI: 10.1161/HYPERTENSIONAHA.116.07286. View

Ma Y, Ye Y, Zhang J, Ruan C, Gao P . Immune imbalance is associated with the development of preeclampsia. Medicine (Baltimore). 2019; 98(14):e15080. PMC: 6455976. DOI: 10.1097/MD.0000000000015080. View

Conrad K, Kerchner L, Mosher M . Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. Am J Physiol. 1999; 277(1 Pt 2):F48-57. DOI: 10.1152/ajprenal.1999.277.1.F48. View

Fukui A, Yokota M, Funamizu A, Nakamua R, Fukuhara R, Yamada K . Changes of NK cells in preeclampsia. Am J Reprod Immunol. 2012; 67(4):278-86. DOI: 10.1111/j.1600-0897.2012.01120.x. View

Anumba D, Robson S, Boys R, Ford G . Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy. Am J Physiol. 1999; 277(2):H848-54. DOI: 10.1152/ajpheart.1999.277.2.H848. View

Townsend R, OBrien P, Khalil A . Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control. 2016; 9:79-94. PMC: 4968992. DOI: 10.2147/IBPC.S77344. View

10.

Zeng Y, Li M, Chen Y, Wang S . Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy. Int J Clin Exp Pathol. 2016; 8(11):15275-9. PMC: 4713666. View

11.

Stillman I, Karumanchi S . The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007; 18(8):2281-4. DOI: 10.1681/ASN.2007020255. View

12.

Spence T, Allsopp P, Yeates A, Mulhern M, Strain J, McSorley E . Maternal Serum Cytokine Concentrations in Healthy Pregnancy and Preeclampsia. J Pregnancy. 2021; 2021:6649608. PMC: 7925069. DOI: 10.1155/2021/6649608. View

13.

Gatford K, Andraweera P, Roberts C, Care A . Animal Models of Preeclampsia: Causes, Consequences, and Interventions. Hypertension. 2020; 75(6):1363-1381. DOI: 10.1161/HYPERTENSIONAHA.119.14598. View

14.

Roberts J, Gammill H . Preeclampsia: recent insights. Hypertension. 2005; 46(6):1243-9. DOI: 10.1161/01.HYP.0000188408.49896.c5. View

15.

Guerin L, Prins J, Robertson S . Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?. Hum Reprod Update. 2009; 15(5):517-35. PMC: 2725755. DOI: 10.1093/humupd/dmp004. View

16.

Mattson D . Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am J Physiol Renal Physiol. 2014; 307(5):F499-508. PMC: 4154114. DOI: 10.1152/ajprenal.00258.2014. View

17.

Bodnar L, Ness R, Markovic N, Roberts J . The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol. 2005; 15(7):475-82. DOI: 10.1016/j.annepidem.2004.12.008. View

18.

Szukiewicz D . Cytokines in placental physiology and disease. Mediators Inflamm. 2012; 2012:640823. PMC: 3425862. DOI: 10.1155/2012/640823. View

19.

Jeyabalan A . Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013; 71 Suppl 1:S18-25. PMC: 3871181. DOI: 10.1111/nure.12055. View

20.

Shentu T, Titushkin I, Singh D, Gooch K, Subbaiah P, Cho M . oxLDL-induced decrease in lipid order of membrane domains is inversely correlated with endothelial stiffness and network formation. Am J Physiol Cell Physiol. 2010; 299(2):C218-29. PMC: 2928623. DOI: 10.1152/ajpcell.00383.2009. View